Get the Stockscreener App
9.58
3.23%
-0.32
After Hours:
9.63
0.05
+0.52%
Lenz Therapeutics Inc stock is traded at $9.58, with a volume of 958.28K.
It is down -3.23% in the last 24 hours and down -21.15% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
See More
Previous Close:
$9.90
Open:
$9.82
24h Volume:
958.28K
Relative Volume:
0.95
Market Cap:
$300.38M
Revenue:
$19.09M
Net Income/Loss:
$-82.13M
P/E Ratio:
-3.4183
EPS:
-2.8026
Net Cash Flow:
$-70.00M
1W Performance:
+1.38%
1M Performance:
-21.15%
6M Performance:
-77.11%
1Y Performance:
-59.90%
1-Day Range:
$9.46
$10.21
1-Week Range:
$8.99
$10.21
52-Week Range:
$8.25
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
9.58 | 310.41M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Squarepoint Ops LLC Acquires Significant Stake in LENZ Therapeutics Inc - GuruFocus
LENZ Therapeutics (LENZ) price target decreased by 20.47% to 39.10 - MSN
Aug Highlights: Can LENZ Therapeutics Inc sustain its profitability2026 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rate Cut: Will LENZ Therapeutics Inc outperform its industry peers2026 Setups & Reliable Intraday Trade Alerts - baoquankhu1.vn
LENZ Stock Price, Quote & Chart | LENZ THERAPEUTICS INC (NASDAQ:LENZ) - ChartMill
Is LENZ Therapeutics Inc stock a smart retirement pickTrade Exit Summary & Entry Point Confirmation Signals - baoquankhu1.vn
Squarepoint entities hold multiple 5% stakes in LENZ (NASDAQ: LENZ) - Stock Titan
Sentiment Recap: What is the cash position of LENZ Therapeutics IncMarket Growth Review & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Insider Spends US$251k Buying More Shares In LENZ Therapeutics - Moomoo
LENZ Therapeutics: Speculative But Strong Buy (NASDAQ:LENZ) - Seeking Alpha
President of LENZ Therapeutics Evert Schimmelpennink Buys 57% More Shares - simplywall.st
President of LENZ Therapeutics Picks Up 57% More Stock - Yahoo Finance
Tech Rally: What is the cash position of LENZ Therapeutics Inc2026 Technical Patterns & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Institution Moves: Is LENZ Therapeutics Inc a strong candidate for buy and holdProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Insider Buying: Jeffrey George Acquires Shares of LENZ Therapeutics Inc (LENZ) - GuruFocus
Lenz Therapeutics CFO Chevallard buys $64k in stock By Investing.com - Investing.com Australia
Lenz Therapeutics director George buys $49,890 in stock By Investing.com - Investing.com Canada
Lenz Therapeutics CEO Schimmelpennink buys $251k in stock By Investing.com - Investing.com Canada
Lenz Therapeutics Insider Bought Shares Worth $251,411, According to a Recent SEC Filing - marketscreener.com
Lenz Therapeutics director George buys $49,890 in stock - Investing.com
Lenz Therapeutics CFO Chevallard buys $64k in stock - Investing.com
Director at LENZ Therapeutics (LENZ) buys 5,592 shares in open-market trade - Stock Titan
LENZ Therapeutics (LENZ) CEO adds 28,089 shares in open-market stock purchase - Stock Titan
LENZ Therapeutics (LENZ) CFO buys 7,500 shares of stock - Stock Titan
LENZ Therapeutics Hits 52-Week Low at USD 10.44 Amid Ongoing Struggles - marketsmojo.com
Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers - simplywall.st
The Consensus EPS Estimates For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Fell Dramatically - Yahoo Finance
Lenz Therapeutics Earnings Call: High Spend, Growing Traction - TipRanks
LENZ Therapeutics Hits 52-Week Low at USD 11.22 Amidst Declining Performance - Markets Mojo
LENZ Therapeutics Hits 52-Week Low at $8.86 Amid Ongoing Struggles - Markets Mojo
LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade) - Seeking Alpha
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week - Yahoo Finance
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
HC Wainwright Issues Positive Forecast for LENZ Earnings - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
LENZ Therapeutics (NASDAQ:LENZ) Price Target Lowered to $26.00 at Citigroup - Defense World
Citigroup Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price - MarketBeat
FY2028 EPS Forecast for LENZ Therapeutics Lowered by Analyst - MarketBeat
Valuation Update: What is the cash position of LENZ Therapeutics Inc2026 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
LENZ Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com UK
Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price - MarketBeat
LENZ Therapeutics stock rating reiterated at Buy by H.C. Wainwright By Investing.com - Investing.com Australia
LENZ Therapeutics, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
LENZ Therapeutics Reports Fourth Quarter, Full-Year Financial Results as Sales of Presbyopia Drop Gain Momentum - VisionMonday.com
VIZZ by LENZ Therapeutics: FDA-Approved Once-Daily Eye Drop for Presbyopia Treatment and Market Opportunity 32 - Minichart
Why Lenz Therapeutics Stock Crashed Today - AOL.com
LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS - MarketBeat
LENZ Therapeutics 2025 10-K: $19.1M Revenue, $(2.85) EPS - TradingView
LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):